Antibody therapeutic - Beijing Immunoah Pharma Tech
Latest Information Update: 26 Jul 2024
At a glance
- Originator Beijing Immunoah Pharma Tech
- Class Analgesics; Antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders; Pain
Most Recent Events
- 01 Jul 2024 Preclinical trials in Autoimmune disorders in China (Parenteral) (Beijing Immunoah pharma pipeline, July 2024)
- 01 Jul 2024 Preclinical trials in Pain in China (Parenteral) (Beijing Immunoah pharma pipeline, July 2024)